Mar 3, 2026 06:00AM
Mar 3, 2026 06:00AM
Jan 11, 2026 06:00PM
Dec 22, 2025 07:06AM
Dec 9, 2025 04:30PM
Nov 21, 2025 08:01AM
Nov 21, 2025 08:00AM Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Nov 19, 2025 08:00AM
Nov 18, 2025 07:02AM
Nov 18, 2025 07:00AM
Nov 10, 2025 08:00AM
Nov 6, 2025 04:30PM
Nov 6, 2025 06:00AM
Nov 4, 2025 08:00AM Esperion names John Harlow as chief commercial officer
Nov 4, 2025 08:00AM
Nov 3, 2025 08:00AM
Oct 28, 2025 08:00AM
Oct 27, 2025 08:00AM
Oct 23, 2025 08:00AM
Oct 16, 2025 08:00AM
Oct 7, 2025 09:29PM Esperion prices $75 million stock offering at $2.50 per share
Oct 7, 2025 09:29PM
Oct 7, 2025 04:02PM
Oct 7, 2025 04:01PM
Oct 3, 2025 08:00AM
Oct 3, 2025 08:00AM
Sep 19, 2025 08:02AM
Sep 19, 2025 08:00AM Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Aug 29, 2025 08:00AM
Aug 26, 2025 08:00AM
Aug 7, 2025 05:30PM
Aug 5, 2025 06:00AM
Jul 22, 2025 08:00AM
Jul 8, 2025 08:01AM
Jul 8, 2025 08:00AM Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Jul 1, 2025 08:07AM
Jul 1, 2025 08:06AM
Jun 2, 2025 08:03AM
Jun 2, 2025 08:00AM
May 20, 2025 08:00AM
May 12, 2025 08:03AM
May 12, 2025 08:00AM Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
May 9, 2025 08:00AM
May 8, 2025 04:30PM
May 8, 2025 06:30AM
May 8, 2025 06:30AM
May 6, 2025 06:00AM
Apr 25, 2025 08:00AM
Apr 24, 2025 08:03AM Esperion Therapeutics (ESPR) Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
Apr 24, 2025 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All